lobbying_activities: 1843030

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1843030	26eae006-e062-4964-a08c-89ae33cdd346	Q2	ACADEMY OF MANAGED CARE PHARMACY	48793	ACADEMY OF MANAGED CARE PHARMACY	2016	second_quarter	PHA	Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy, providing comments to the FDA on the impact of Risk Evaluation Mitigation Strategies (REMS), supporting H.R. 2841 designed to increase access to generic drugs and providing comments to CMS on benefit and payment parameters for 2017. Support S. 524 (CARA). Comments provided to SAMSHA and AHRQ on opioid abuse. Comments provided on S. 2700 concerning an exemption for biological medicines from USP standards for quality. Comments provided to CMS on MACRA proposed rule.	Agency for Healthcare Research & Quality (AHRQ),Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)		188000	0	0	2016-07-15T10:33:58.977000-04:00